The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for TPG Asia VII SF Pte Ltd
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
TPG Asia VII SF Pte Ltd, a Singapore-based private equity fund and non-promoter shareholder, has sold its entire holding of 3,07,06,833 equity shares (14.72% of the paid-up capital) in Sai Life Sciences Ltd through an on-market transaction on August 26, 2025. This represents a complete exit by TPG from the company, reducing its shareholding from 14.72% to nil. The disclosure was filed under Regulation 29(2) of the SEBI SAST Regulations, and the shares were sold at face value of INR 1 each. Sai Life Sciences' total equity share capital remains INR 20,85,45,302 (20.85 crore shares), with an additional 69.31 lakh outstanding ESOPs forming part of the diluted capital.
This is a significant supply event for the stock as a large institutional holder has fully exited, which could weigh on the share price due to potential selling pressure and reduced institutional sponsorship. However, it also means the overhang from this PE investor is now cleared, and the company may attract new long-term institutional investors.